A Phase 1 interventional study of Intravenous fosmanogepix and Intravenous fosmanogepix in End Stage Renal Disease on Dialysis and Adult, sponsored by Basilea Pharmaceutica. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 451st largest by planned enrollment of the 638 interventional ones that give a count, is one of 22 that started in 2026, is one of 89 in phase 1, reaches primary completion later than 56 of the 95 other live ones, and was the 765th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:
United Therapeutics · Sites in United States
Ages 40–70
Xeno Holdings (US), LLC dba ChoironeX · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
Bristol-Myers Squibb · Sites in United States
Ages 18–84 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
765 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 130 · Phase 3 89 · Phase 4 61
First in 1995; this study’s year is marked. 22 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 48 across the 638 interventional studies, 100 across the 121 observational. Of the 611 that completed or were terminated, 267 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 765 have an industry lead sponsor. The 10 most frequent:
Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.
Basilea Pharmaceutica has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
43 of the studies in Kidney Failure, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT05931276Phase 3VA Office of Research and DevelopmentCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | 2026-12-31 |
| NCT03321656Phase 3Roberto GedalyImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | 2027-03-31 |
| NCT05908084Phase 3Humacyte, Inc.To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | 2027-06 |
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate how fosmanogepix is processed by the body (pharmacokinetics, PK) in participants with kidney failure (end-stage renal disease (ESRD) requiring intermittent hemodialysis (IHD) compared with participants with normal kidney function (control group). Fosmanogepix is given by intravenous infusion and is converted in the body to manogepix, the active form of the drug. Fosmanogepix is an investigational and has not been approved by the United States Food and Drug Administration (FDA) or any other regulatory authority for use in humans.
The study will also evaluate the effect of hemodialysis on manogepix levels in participants with ESRD.
The safety and tolerability of fosmanogepix will also be assessed in participants with kidney failure and in matched participants with normal kidney function.
Participation in the study will last up to 11 weeks and will include up to two study periods. Participants with ESDR requiring IHD will receive fosmanogepix in two study periods. Healthy participants will receive fosmanogepix in one study period.
The study will be conducted at two study sites in the United States.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with ESRD requiring IHD only:
-Not on stable dosing regimen (i.e., \< 3 weeks prior to Screening) of prescription/ non prescription drugs (including dietary/herbal supplements) for the treatment of a stable concomitant disease
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with end stage renal disease (ESRD) requiring intermittent hemodialysis (IHD)
Drug: Intravenous fosmanogepix
Participants with normal renal function (control group)
Drug: Intravenous fosmanogepix
Two doses of intravenous fosmanogepix will be administered on Day 1 and Day 2.
Two doses of intravenous fosmanogepix will be administered on Day 1 and Day 2 in each period (Period 1 and 2)
Maximum Plasma Concentration (Cmax) of manogepix
Cmax of manogepix will be assessed in participants with ESRD in Period 2 and compared with that of healthy participants in Period 1.
Time frame: Blood sampling in Period 1: At Day 1, 2, 3, 4, 5 and 6. Blood sampling in Period 2: At Day 1, 2, 3, 4, 5, 6, 8, 11, 13 and 15.
Area under the concentration-time curve (AUC) of manogepix
AUC of manogepix will be assessed in participants with ESRD in Period 2 and compared with that of healthy participants in Period 1.
Time frame: Blood sampling in Period 1: At Day 1, 2, 3, 4, 5 and 6. Blood sampling in Period 2: At Day 1, 2, 3, 4, 5, 6, 8, 11, 13 and 15.
Impact of IHD on the AUC of manogepix (total and unbound) in Periods 1 and 2
Impact of IHD on the AUC of manogepix (total and unbound) in Periods 1 and 2 will be assessed after fosmanogepix IV administration in subjects with ESRD requiring IHD.
Time frame: Blood sampling in Period 1: At Day 1, 2, 3, 4, 5 and 6. Blood sampling in Period 2: At Day 1, 2, 3, 4, 5, 6, 8, 11, 13 and 15.
Impact of IHD on the Tmax of manogepix (total and unbound) Periods 1 and 2
Impact of IHD on the Tmax of manogepix (total and unbound) will be assessed in Periods 1 and 2 after fosmanogepix IV administration in subjects with ESRD requiring IHD.
Time frame: Blood sampling in Period 1: At Day 1, 2, 3, 4, 5 and 6. Blood sampling in Period 2: At Day 1, 2, 3, 4, 5, 6, 8, 11, 13 and 15.
Impact of IHD on the Cmax of manogepix (total and unbound) Periods 1 and 2
Impact of IHD on the Cmax of manogepix (total and unbound) will be assessed in Periods 1 and 2 after fosmanogepix IV administration in participants with ESRD requiring IHD.
Time frame: Blood sampling in Period 1: At Day 1, 2, 3, 4, 5 and 6. Blood sampling in Period 2: At Day 1, 2, 3, 4, 5, 6, 8, 11, 13 and 15.
Number of participants reporting treatment emergent adverse events (TEAEs)
To evaluate the safety and tolerability of fosmanogepix in participants with ESRD requiring IHD, and in healthy participants.
Time frame: From screening to up to 35 days after last study drug administration.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Nov 2027, 12 months after the start.
Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 12 months is above that.
Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.